We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Finger Prick Test Could Transform Heart Attack Prevention

By LabMedica International staff writers
Posted on 14 Feb 2025

Currently, blood-thinning medications are prescribed only to patients who have already experienced a heart attack or stroke, as these drugs can lead to serious bleeding in some individuals. More...

Due to the lack of a reliable method to predict who may benefit or be harmed by these medications, doctors have been unable to prescribe them preventively to high-risk patients. Now, a new study suggests that a simple scoring system could transform how doctors prevent heart attacks and strokes by identifying patients who are most likely to benefit from preventive treatment.

The innovative test, known as the TRIPLE Score, was developed by researchers at the University of Reading (Berkshire, UK). It measures specific proteins on blood platelets, along with the patient's age, to help doctors make better-informed decisions about prescribing blood-thinning medications like aspirin and clopidogrel. Although the test is not yet widely available, the goal is to eventually make it suitable for point-of-care use. It will be incorporated into patient studies to verify its potential to enhance care.

In their study, published in Circulation Research, the team demonstrated that the TRIPLE Score effectively identified patients whose blood was more prone to forming clots in laboratory tests. The findings also correlated with established risk scores used by doctors to estimate a patient’s likelihood of having a heart attack within the next 10 years. The test requires just a small blood sample and could be developed into a simple tool that healthcare providers, not just specialists, could use in practice.

“Our new test will help doctors make sure that patients receive the best treatment and keep their quality of life,” said Dr. Alexander Bye, lead author of the research at the University of Reading. “Next, we aim to make the test even easier to use by developing a finger prick test, so that it as simple as measuring blood glucose."


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.